Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 4
1987 1
1992 1
1993 3
1994 3
1995 3
1996 1
1998 4
1999 1
2000 1
2001 4
2002 17
2003 27
2004 65
2005 82
2006 109
2007 115
2008 108
2009 141
2010 113
2011 127
2012 146
2013 147
2014 155
2015 141
2016 151
2017 118
2018 101
2019 104
2020 113
2021 130
2022 101
2023 134
2024 130
2025 128
2026 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,379 results

Results by year

Filters applied: . Clear all
Page 1
Atomoxetine.
Unni JC. Unni JC. Indian Pediatr. 2006 Jul;43(7):603-6. Indian Pediatr. 2006. PMID: 16891679 Free article. Review. No abstract available.
Atomoxetine.
Simpson D, Perry CM. Simpson D, et al. Paediatr Drugs. 2003;5(6):407-15; discussion 416-7. doi: 10.2165/00128072-200305060-00005. Paediatr Drugs. 2003. PMID: 12765489 Review.
Atomoxetine, formerly tomoxetine, is a selective norepinephrine reuptake inhibitor and a new, nonstimulant treatment for attention deficit hyperactivity disorder (ADHD). ...Atomoxetine was well tolerated in clinical trials and discontinuation rates due to adverse ev
Atomoxetine, formerly tomoxetine, is a selective norepinephrine reuptake inhibitor and a new, nonstimulant treatment for attention de
Methylphenidate and Atomoxetine in Pregnancy and Possible Adverse Fetal Outcomes: A Systematic Review and Meta-Analysis.
di Giacomo E, Confalonieri V, Tofani F, Clerici M. di Giacomo E, et al. JAMA Netw Open. 2024 Nov 4;7(11):e2443648. doi: 10.1001/jamanetworkopen.2024.43648. JAMA Netw Open. 2024. PMID: 39504019 Free PMC article.
OBJECTIVE: To examine adverse effects in offspring of mothers receiving treatment with atomoxetine and methylphenidate during pregnancy. DATA SOURCES: Electronic databases (PubMed, Embase, and PsycINFO) were searched for articles published through December 31, 2023, with t …
OBJECTIVE: To examine adverse effects in offspring of mothers receiving treatment with atomoxetine and methylphenidate during pregnan …
Atomoxetine-Associated Angular Cheilitis.
Kirlioglu SS, Unaldi N. Kirlioglu SS, et al. Am J Ther. 2022 Sep-Oct 01;29(5):e605-e606. doi: 10.1097/MJT.0000000000001168. Epub 2020 Mar 25. Am J Ther. 2022. PMID: 32235145 No abstract available.
Atomoxetine in-focus!
Naguy A, Al-Enezi N, AlShalabi SR. Naguy A, et al. Asian J Psychiatr. 2020 Mar;49:101634. doi: 10.1016/j.ajp.2019.02.008. Epub 2019 Feb 13. Asian J Psychiatr. 2020. PMID: 30797701 No abstract available.
Personalizing atomoxetine dosing in children with ADHD: what can we learn from current supporting evidence.
Fu D, Guo HL, Hu YH, Fang WR, Liu QQ, Xu J, Wu DD, Chen F. Fu D, et al. Eur J Clin Pharmacol. 2023 Mar;79(3):349-370. doi: 10.1007/s00228-022-03449-1. Epub 2023 Jan 16. Eur J Clin Pharmacol. 2023. PMID: 36645468 Review.
PURPOSE: There is marked heterogeneity in treatment response of atomoxetine in patients with attention deficit/hyperactivity disorder (ADHD), especially for the pediatric population. This review aims to evaluate current evidence to characterize the dose-exposure relationsh …
PURPOSE: There is marked heterogeneity in treatment response of atomoxetine in patients with attention deficit/hyperactivity disorder …
Atomoxetine for suppression of vasovagal syncope.
Sheldon RS, Seifer C, Parkash R, Sandhu RK, Hamzeh R, Raj SR. Sheldon RS, et al. Clin Auton Res. 2023 Feb;33(1):23-28. doi: 10.1007/s10286-022-00905-x. Epub 2022 Nov 19. Clin Auton Res. 2023. PMID: 36401665 Clinical Trial.
The study aimed to evaluate the effectiveness of atomoxetine in suppressing syncope in patients with recurrent VVS. METHODS: This was a retrospective, open-label, observational case series of 12 patients taking atomoxetine for suppression of recurrent vasovagal sync …
The study aimed to evaluate the effectiveness of atomoxetine in suppressing syncope in patients with recurrent VVS. METHODS: This was …
Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.
Brown JT, Bishop JR. Brown JT, et al. Pharmacogenomics. 2015;16(13):1513-20. doi: 10.2217/PGS.15.93. Epub 2015 Aug 28. Pharmacogenomics. 2015. PMID: 26314574 Review.
Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder and is predominantly metabolized by the CYP2D6 enzyme. ...Furthermore, pharmacokinetic and clinical studies have primarily focused on extensive as compared with poor metabolizers, with l
Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder and is predominantly metabolized by the CYP2D6
Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.
Yu G, Li GF, Markowitz JS. Yu G, et al. J Child Adolesc Psychopharmacol. 2016 May;26(4):314-26. doi: 10.1089/cap.2015.0137. Epub 2016 Feb 9. J Child Adolesc Psychopharmacol. 2016. PMID: 26859445 Free PMC article. Review.
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children (6 years of age), adolescents, and adults. ...The present review focuses on atomoxetine metabolism, dispositio
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor approved for the treatment of attention-deficit/hyperactivity disor
[Atomoxetine for treatment of children and adolescents with ADHD].
Resen K, Pagsberg AK, Jörgens G. Resen K, et al. Ugeskr Laeger. 2014 Mar 3;176(10A):V07130447. Ugeskr Laeger. 2014. PMID: 25350704 Free article. Review. Danish.
Atomoxetine reduces ADHD symptoms in children and adolescents significantly and is indicated for ADHD with co-morbid anxiety, depression and tics or with an increased risk of abuse. ...In most cases adverse effects are mild to moderate and transient. Since atomoxetine
Atomoxetine reduces ADHD symptoms in children and adolescents significantly and is indicated for ADHD with co-morbid anxiety, depress
2,379 results